Literature DB >> 8308860

Rational modification of human synovial fluid phospholipase A2 inhibitors.

M T Pisabarro1, A R Ortiz, A Palomer, F Cabré, L García, R C Wade, F Gago, D Mauleón, G Carganico.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8308860     DOI： 10.1021/jm00029a004

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  4 in total

Review 1.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

2.  PRO_SELECT: combining structure-based drug design and combinatorial chemistry for rapid lead discovery. 1. Technology.

Authors:  C W Murray; D E Clark; T R Auton; M A Firth; J Li; R A Sykes; B Waszkowycz; D R Westhead; S C Young
Journal:  J Comput Aided Mol Des       Date:  1997-03       Impact factor: 3.686

3.  Mechanism of inhibition of human secretory phospholipase A2 by flavonoids: rationale for lead design.

Authors:  Jens Lättig; Markus Böhl; Petra Fischer; Sandra Tischer; Claudia Tietböhl; Mario Menschikowski; Herwig O Gutzeit; Peter Metz; M Teresa Pisabarro
Journal:  J Comput Aided Mol Des       Date:  2007-08-15       Impact factor: 3.686

4.  Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2.

Authors:  R W Schevitz; N J Bach; D G Carlson; N Y Chirgadze; D K Clawson; R D Dillard; S E Draheim; L W Hartley; N D Jones; E D Mihelich
Journal:  Nat Struct Biol       Date:  1995-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.